Lena Margarethe Wulfken Jürgen Christian Becker Rami Hayajneh Annette Doris Wagner Katrin Schaper-Gerhardt Nina Flatt Imke Grimmelmann Ralf Gutzmer
10.3389/fimmu.2021.733961
Front Immunol
2021 Oct 5;12:733961.
b cell depletion cd20 case report immune checkpoint blockade melanoma
CC BY
https://pubmed.ncbi.nlm.nih.gov/34675925/
B-Lymphocytes, Regulatory / immunology Granulomatosis with Polyangiitis / drug therapy Immune Checkpoint Inhibitors / therapeutic use Melanoma / drug therapy Nivolumab / therapeutic use Programmed Cell Death 1 Receptor / metabolism Skin Neoplasms / drug therapy
B-Lymphocytes, Regulatory / immunology Granulomatosis with Polyangiitis / drug therapy Immune Checkpoint Inhibitors / therapeutic use Melanoma / drug therapy Nivolumab / therapeutic use Programmed Cell Death 1 Receptor / metabolism Skin Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Female Humans Interleukin-10 / metabolism Lymphocyte Depletion Middle Aged Neoplasm Metastasis Programmed Cell Death 1 Receptor / antagonists & inhibitors Remission Induction Rituximab / therapeutic use Immune Checkpoint Inhibitors Programmed Cell Death 1 Receptor Interleukin-10 Nivolumab Rituximab
PMC8525286
34675925
Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells
2021